WASHINGTON, DC – The US Food and Drug Administration has approved two clinical trials to assess the efficacy of cannabidiol (CBD), a nonpsychoactive plant cannabinoid, in the treatment of intractable pediatric epilepsy. The two approved trials will take place at New York Medical School and at the University of California at San Francisco, according to an online report in the […]
Read FDA Approves Clinical Trials Assessing CBD for Pediatric Epilepsy in its entirety on The Daily Chronic.
Want to stay up to date on marijuana reform & cannabis news worldwide? Visit The Daily Chronic - The Voice of the Reform Generation, the most comprehensive coverage of the cannabis community!READ MORE
LONDON — The inhalation of the non-psychoactive cannabinoid CBD (cannabidiol) significantly mitigates tobacco smokers’ desire for cigarettes, according to clinical trial data published online in the journal Addictive Behaviors.
Investigators at University College London conducted a double blind pilot study to assess the impact of the ad-hoc consumption of organic CBD versus placebo in 24 tobacco-smoking subjects seeking to quit their habit. Participants were randomized to receive an inhaler containing CBD (n=12) or placebo (n=12) for one week. Trial investigators instructed subjects to use the inhaler when they felt the urge to smoke.
Researchers reported: “Over the treatment week, placebo treated smokers showed no differences in number of cigarettes smoked. In contrast, those treated with CBD significantly reduced the number of cigarettes smoked by [the equivalent of] 40 percent during treatment.” Moreover, participants who used CBD did not report experiencing increased cravings for nicotine during the study’s duration.
Investigators concluded, “This is the first study, as far as we are aware, to demonstrate the impact of CBD on cigarette smoking…. These preliminary data, combined with the strong preclinical rationale for use of this compound, suggest CBD to be a potential treatment for nicotine addiction that warrants further exploration.”
Previously publishe. . . . . READ MORE
Preclinical study data published online in the scientific journal Nutrition & Diabetes reports that tetrahydrocannabivarin (THCV) — a naturally occurring analogue of THC — possesses positive metabolic effects in animal models of obesity.
British researchers assessed the effects of THCV administration on dietary-induced and genetically modified obese mice. Authors reported that although THCV administration did not significantly affect food intake or body weight gain in any of the models, it did produce several metabolically beneficial effects, including reduced glucose intolerance, improved glucose tolerance, improved liver triglyceride levels, and increased insulin sensitivity.
Researchers concluded: “Based on these data, it can be suggested that THCV may be useful for the treatment of the metabolic syndrome and/or type 2 diabetes (adult onset diabetes), either alone or in combination with existing treatments. Given the reported benefits of another non-THC cannabinoid, CBD in type 1 diabetes, a CBD/THCV combination may be beneficial for different types of diabetes mellitus.”